Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Comparison of Cytokines in Skin Biopsies and Tape Strips from Adults with Atopic Dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Comparison of Cytokines in Skin Biopsies and Tape Strips from Adults with Atopic Dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Chromium and cobalt release from metallic earrings from the Danish market

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. No immediate effect of regulatory reduction of chromium in leather among adult patients with chromium allergy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Bariatric surgery and risk of new-onset inflammatory bowel disease: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Wide fluctuations in placebo responses have been reported in phase 3 trials of systemic therapies for moderate-to-severe plaque psoriasis.

METHODS: In this systematic review and meta-analysis, we assessed placebo responses in phase 3 trials of systemic therapies for moderate-to-severe plaque psoriasis. The medical databases PubMed Medline, Embase, and Web of Science were searched for studies reporting on phase 3 psoriasis trials. A proportion meta-analysis determined the proportion of placebo-treated psoriasis patients obtaining a 75, 90, or 100% reduction in Psoriasis Area and Severity Index (PASI), that is, PASI75, PASI90, or PASI100, respectively, at week 12. In the assessment of PASI75 response, 44 trials with a total number of 7,972 patients were included.

CONCLUSION: In pooled analyses, 5.2% (95% CI 4.7-5.7%) obtained PASI75, 2.1% (95% CI 1.7-2.4%) obtained PASI90, and 0.3% (95% CI 0.1-0.5%) obtained PASI100 among placebo receivers. No temporal changes were observed. The overall proportion of placebo responders in phase 3 psoriasis trials is low and does not appear to be increasing in recent years.

OriginalsprogEngelsk
TidsskriftDermatology
Vol/bind237
Udgave nummer2
Sider (fra-til)158-165
Antal sider8
ISSN1018-8665
DOI
StatusUdgivet - mar. 2021

ID: 67626121